An injection cut visceral fat 12.01% in a trial where the placebo group gained it

Caliway Biopharmaceuticals reported that its experimental fat-cell injection, CBL-514, reduced visceral fat volume by an average of 12.01% four weeks after the last dose, while participants given placebo saw theirs grow by 5.68%. The figures were presented at the European Association for the Study of Diabetes annual meeting in Milan, Italy, in October 2026, and they come from phase two work in a small group of adults with a body mass index between 22 and 30. The drug is not approved anywhere, and this is trial data in a selected population rather than a general weight-loss claim.

An Injection That Instructs Fat Cells to Die

CBL-514 is a small-molecule drug from Taiwan-based Caliway that is designed to trigger apoptosis, the programmed death of fat cells, while leaving other cell types alone. That distinguishes it from the incretin drugs now dominating obesity medicine, which suppress appetite and shrink existing fat cells rather than removing them.

Visceral fat is the deep abdominal fat that wraps the organs, and it is the depot most closely tied to metabolic disease. Until now a needle aimed at it has not been on the menu, because earlier fat-dissolving injections were developed for visible, subcutaneous pockets under the skin. The idea, as the conference summary carried by ScienceDaily describes it, is that fewer fat cells could mean less capacity to store fat later.

In the pooled analysis, patients received up to 600 mg of CBL-514 injected into the lower abdomen every three weeks for up to 12 weeks, with the number of injections depending on abdominal fat thickness and stopping once thickness fell below a set threshold. The company also reports that in the same phase two program, 69.6% of treated participants lost at least 150 mL of subcutaneous fat by week eight, against none on placebo. That figure measures a different fat compartment from the 12.01% visceral figure, and the denominator was not given.

A Subgroup Analysis of Two Phase Two Studies

The visceral result is a subgroup analysis of two phase two studies, CBL-0204 and CBL-0205, rather than a stand-alone trial. According to News-Medical’s account of the presentation, 41 participants had MRI scans: 23 on CBL-514 and 18 on placebo, with 40 followed to the later time point. Baseline visceral fat averaged 563.85 mL in the treated group and 659.81 mL in the placebo group, and the 12.01% is the average of each person’s percentage change from his or her own baseline, not a change in the group average. The reports do not label the visceral measure as a primary or secondary endpoint, and the studies were built mainly around subcutaneous abdominal fat.

The Placebo Arm Moved the Wrong Way

The striking detail is the control group. Placebo participants did not hold steady; their visceral fat rose 5.68% at four weeks, giving a gap of 17.69 percentage points between arms. At the later check, eight weeks after the final injection in one study and twelve in the other, CBL-514 recipients were still 10.45% below baseline while placebo recipients were 11.76% above it, a gap of 22.21 points. Neither report explains why placebo visceral fat climbed, and a rise of that size in a short window may reflect natural variation in small groups, MRI measurement noise or lifestyle drift as much as anything about the drug.

That matters for how the 12.01% figure should be read. Part of the 17.69-point gap is the control group rising, not only the treated group falling, so the treated arm’s own 12.01% drop is the more conservative number to quote.

Detailed statistics are also uneven across accounts. The ScienceDaily summary gives no p-values, and a separate report on the same abstract from HCPLive cites a pooled set of 46 patients, 26 on CBL-514 and 20 on placebo, with a week-four reduction of 10.9% versus a 4.6% rise on placebo and a P value of .0019 for the percent-change comparison. Slightly different analysis sets produce slightly different numbers, which is one reason the exact 12.01% should be attributed to the specific summary that reported it.

What Remains Unproven About CBL-514

Safety looked clean on paper: reports describe mostly mild to moderate, temporary injection-site pain, swelling and redness, and no serious adverse events. Incidence rates, discontinuations and comparator rates were not provided, and the participants were relatively young, with mean ages between 36.4 and 42.4 years across groups, and not heavily obese.

W. Timothy Garvey of the University of Alabama at Birmingham, who is named alongside Caliway’s Yu-Fang Ling in the presentation, called it a “highly innovative approach to obesity pharmacotherapy.” He has pointed to weight reduction, visceral fat loss and related improvements in blood pressure and cholesterol as the benefits that matter for health, but those outcomes have not yet been demonstrated for this drug, and the data presented here are conference results, not a peer-reviewed publication.

The next evidence is already in motion. Caliway announced that its pivotal phase three trial SUPREME-01 has begun enrolling, as set out in the company’s August release, which also describes a roughly 120-person randomized phase two study of CBL-514 combined with tirzepatide, cleared by the U.S. Food and Drug Administration for investigational use. In that study visceral fat is an exploratory endpoint, not the primary one. Readers following the program can check the registered studies through a ClinicalTrials.gov search for CBL-514.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview